Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6830075 | 0.82 | HMGCR (0.32) | HMGCR | |
| SCHEMBL17291956 | 0.78 | PTGDR2 (0.35) | PTGDR2 | |
| SCHEMBL1729127 | 0.77 | PTGDR2 (0.37) | PTGDR2 | |
| SCHEMBL1729169 | 0.75 | PTGDR2 (0.35) | PTGDR2 | |
| SCHEMBL1729069 | 0.75 | ALDH1A1 (0.41) | PTGDR2 | |
| SCHEMBL8807107 | 0.71 | ALDH1A1 (0.39) | — | |
| SCHEMBL5086986 | 0.69 | CYP2D6 (0.38) | — | |
| SCHEMBL6033258 | 0.69 | ALDH1A1 (0.36) | — | |
| SCHEMBL28734927 | 0.69 | CA2 (0.46) | — | |
| SCHEMBL9161090 | 0.68 | DHFR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743923-B2 | A BENZYLIDENE DERIVATIVES USED FOR OSTEOCLAST FORMATION INHIBITION, A NITROGEN MONOXIDE PRODUCTION INHIBITION, AND A TRANSCRIPTION FACTOR NF KAPPA B SUPRESSING AGENT | SHIONOGI & CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20030125364-A1 | Antirheumatic agent | MATSUMOTO SAICHI (JP) | 2003-07-03 | — | — | US | disclosed |
| US-6525081-B1 | Inhibiting osteoclast formation and nitrogen monoxide production; suppressing transcription factor NF kappa B | SHIONOGI & CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1026162-A1 | ANTIRHEUMATIC | SHIONOGI & CO., LTD. (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125364-A1 | Antirheumatic agent | IL1A, IL1B, IL17A | PTGDR2 267/4885HMGCR 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.